Cargando…
Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal
BACKGROUND: Plasmodium vivax is the main cause of malaria in Nepal. Relapse patterns have not been characterized previously. METHODS: Patients with P. vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0.25 mg base/kg/day...
Autores principales: | Rijal, Komal Raj, Adhikari, Bipin, Ghimire, Prakash, Banjara, Megha Raj, Das Thakur, Garib, Hanboonkunupakarn, Borimas, Imwong, Mallika, Chotivanich, Kesinee, Day, Nicholas P J, White, Nicholas J, Pukrittayakamee, Sasithon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603971/ https://www.ncbi.nlm.nih.gov/pubmed/30882150 http://dx.doi.org/10.1093/infdis/jiz126 |
Ejemplares similares
-
Epidemiology of Plasmodium vivax Malaria Infection in Nepal
por: Rijal, Komal Raj, et al.
Publicado: (2018) -
A Comparison of Two Short-Course Primaquine Regimens for the Treatment and Radical Cure of Plasmodium vivax Malaria in Thailand
por: Pukrittayakamee, Sasithon, et al.
Publicado: (2010) -
Artemisinin resistance and malaria elimination: Where are we now?
por: Hanboonkunupakarn, Borimas, et al.
Publicado: (2022) -
K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar
por: Win, Aye A., et al.
Publicado: (2016) -
Erratum to: K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar
por: Win, Aye A., et al.
Publicado: (2016)